Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment

doi:10.1111/jvh.13265

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24877

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24877

Title:	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment
Authors:	Liu, CH;Yang, SS;Peng, CY;Lin, WT;Liu, CJ;Su, TH;Tseng, TC;Chen, PJ;Chen, DS;Kao, JH
Keywords:	chronic kidney disease;direct-acting antiviral agent;glecaprevir;hepatitis C virus;pibrentasvir
Date:	2020
Issue Date:	2022-08-09T08:09:27Z (UTC)
Publisher:	WILEY
ISSN:	1352-0504
Abstract:	Data are limited regarding the real-world effectiveness and safety of glecaprevir/pibrentasvir (GLE/PIB) in patients with chronic hepatitis C virus (HCV) infection and severe renal impairment (RI). We aimed to evaluate the performance of GLE/PIB in patients with chronic kidney disease (CKD) stage 4 or 5 in Taiwan. 108 chronic HCV patients with CKD stage 4 (n = 32) or 5 (n = 76) receiving GLE/PIB for 8-12 weeks were retrospectively recruited at 4 academic centres in Taiwan. The effectiveness was determined by sustained virologic response at off-therapy week 12 (SVR12) for evaluable (EP) and per-protocol populations (PP). The safety profiles were also assessed. By EP and PP analyses, the SVR12 rate was 99.1% (107 of 108 patients; 95% confidence interval (CI): 94.9%-99.8%) and 100% (107 of 107 patients; 95% CI: 96.5%-100%). The SVR12 rates were 100% (95% CI: 89.3%-100%) and 98.7% (95% CI: 92.9%-99.8%) in patients with CKD stage 4 and 5, respectively. One patient, who declined off-therapy follow-up after permanently discontinuing GLE/PIB at on-treatment week 9 due to scheduled cardiac surgery, had nonvirologic failure. Sixteen (14.8%) patients had serious adverse events (AEs), which were judged not related to GLE/PIB. The three most common AEs were pruritus (19.4%), fatigue (15.7%) and nausea (13.9%). None had >= 3-fold upper limit of normal for total bilirubin and alanine aminotransferase levels. None of the 9 patients with hepatitis B virus (HBV) coinfection developed HBV-associated hepatitis. In conclusion, GLE/PIB for 8-12 weeks is effective and well-tolerated in HCV patients with severe RI.
URI:	http://dx.doi.org/10.1111/jvh.13265 https://www.webofscience.com/wos/woscc/full-record/WOS:000511267200001 https://ir.csmu.edu.tw:8080/handle/310902500/24877
Relation:	JOURNAL OF VIRAL HEPATITIS ,2020 ,v27 ,issue 6 ,p568-575
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	149	View/Open

Loading...